Scientific publications
Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells
Sep 14, 2015
| Magazine: Cancer Cell
San Miguel JF (1), Paiva B (2), Lasarte JJ (2).
(1) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain.
(2) Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain.
ABSTRACT
NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors.
Recent work supports their use in multiple myeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bone marrow, are well tolerated, and produce promising response rates when infused after stem cell transplantation.
CITATION Cancer Cell. 2015 Sep 14;28(3):281-3. doi: 10.1016/j.ccell.2015.08.009.
Our authors
